Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Common Equity: 2023-2024

Historic Common Equity for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Dec 2024 value amounting to $222.9 million.

  • Monte Rosa Therapeutics' Common Equity rose 19.65% to $245.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $245.8 million, marking a year-over-year increase of 19.65%. This contributed to the annual value of $222.9 million for FY2024, which is 24.37% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Common Equity is $222.9 million, which was up 24.37% from $179.2 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Common Equity ranged from a high of $222.9 million in FY2024 and a low of $179.2 million during FY2023.
  • Moreover, its 2-year median value for Common Equity was $201.1 million (2023), whereas its average is $201.1 million.
  • Data for Monte Rosa Therapeutics' Common Equity shows a peak YoY climbed of 24.37% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Common Equity (Yearly) stood at $179.2 million in 2023, then climbed by 24.37% to $222.9 million in 2024.